Brentuximab Vedotin Studies Explore Novel Combinations, Pretransplant Settings
January 30th 2014Alison J. Moskowitz, MD, is among researchers at Memorial Sloan-Kettering Cancer Center and elsewhere who are investigating an expanded role for the CD30-targeting brentuximab vedotin (Adcetris) in hematologic malignancies. Moskowitz specializes in the treatment of patients with lymphoma and her research focuses on evaluating novel treatments for Hodgkin lymphoma.
"N of 1" Research: Molecular Findings Create Urgency for New Drug Discovery Paradigm
January 13th 2014There has been considerable discussion within the oncology literature during the past several years regarding the level of evidence required to consider a new antineoplastic agent an acceptable "standard-of-care" in routine disease management.
Fisher's Respect for Scientific Methods Propelled Landmark Advances
January 10th 2014When Bernard Fisher, MD, first became involved in breast cancer research, the only treatment option available to patients was the radical mastectomy, a horribly disfiguring surgery that had been the undisputed standard of care since the late 1800s
B-Cell Malignancies: Transforming Expectations and Outcomes
January 6th 2014With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.
Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment
January 3rd 2014Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.
Reality Check Needed: Comorbidities Loom in Practice, But Not in Clinical Trials
January 2nd 2014How should the dose and schedule of antineoplastic therapies be modified in patients with known chronic liver, cardiac, or pulmonary disease when these conditions were excluded from the trials that permitted their routine clinical use? How should treatment be changed in the presence of significant obesity?
Model Emerges for Targeting Oncogenes in NSCLC
December 30th 2013Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of non-small cell lung cancer, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of anaplastic lymphoma kinase.
PCPT Trial Helps Confirm Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention
December 17th 2013Two years after the FDA denied a request to expand the indication of finasteride and other 5α-reductase inhibitors to prevent prostate cancer, a major study has cast doubt on the concerns that prompted the denial: that the drug raised the risk of more lethal cancers.
Predicting Risk of Aggressive Prostate Cancer Through Biomarkers in Blood
December 16th 2013A new study has shown a possible correlation between men with short-ended chromosomes in the immune cells of their blood and an increased risk of developing aggressive prostate cancer, potentially pointing the way toward an accessible biomarker that could help inform treatment and surveillance decisions.